Should phenylpropanolamine combined with brompheniramine maleate syrup and procaterol 5 µg/5 mL be administered to children younger than five years?

Do Not Use This Combination in Children Below 5 Years Old

The phenylpropanolamine + brompheniramine maleate combination should be avoided in all children below 6 years of age due to documented fatalities and lack of proven efficacy, and procaterol use in this age group lacks adequate safety data. 1

Critical Safety Concerns with Phenylpropanolamine + Brompheniramine

Documented Mortality Risk

Between 1969 and September 2006, the FDA Adverse Event Reporting System documented:

• 54 fatalities associated with decongestants (including phenylpropanolamine) in children ≤6 years, with 43 deaths occurring in infants under 1 year
• 69 fatalities associated with antihistamines, including 9 deaths specifically from brompheniramine in children ≤6 years, with 41 deaths in children under 2 years 1

Common causes of these deaths included drug overdose, use of multiple cold/cough products simultaneously, medication errors, and accidental exposures 1.

Lack of Efficacy

Controlled trials have definitively shown that antihistamine-decongestant combination products are not effective for upper respiratory tract infection symptoms in young children 1. The FDA's Nonprescription Drugs and Pediatric Advisory Committees recommended in October 2007 that OTC cough and cold medications should not be used in children below 6 years of age 1.

FDA Drug Label Restrictions

The brompheniramine maleate FDA label explicitly states:

• Contraindicated in nursing mothers due to higher risk of intolerance in small infants, newborns, and prematures
• Safety and effectiveness not established in children below 6 months of age
• For infants 6 months to under 2 years: "Dosage to be established by a physician" (indicating lack of standard safety data) 2

Procaterol Concerns in Young Children

Insufficient Pediatric Data

While procaterol has been studied in older asthmatic children with acceptable safety profiles 3, 4, there is:

• No adequate safety or efficacy data for children under 5 years
• Limited published evidence in the very young pediatric population
• Asthma treatment in young children, especially infants, has not been studied adequately, with most recommendations based on extrapolations from older children 5

Appropriate Alternatives for Asthma (if indicated)

If bronchodilator therapy is truly needed for asthma in children under 5 years, the evidence-based approach is:

• Inhaled corticosteroids (ICS) are the preferred long-term control medication 5
• FDA-approved options for young children include:
  • Budesonide nebulizer solution (ages 1-8 years)
  • Montelukast granules (down to 1 year old) 5

Common Pitfalls to Avoid

1. Polypharmacy errors: Using multiple cough/cold products simultaneously dramatically increases overdose risk 1

2. Misdiagnosis: Not all wheeze and cough in young children is asthma—viral respiratory infections are the most common cause of respiratory symptoms in this age group 5

3. Inappropriate prolonged therapy: Even if asthma therapy is warranted, response should be monitored closely with reassessment at 4-6 weeks 5

4. Ignoring safer alternatives: Second-generation antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) have been shown to be well-tolerated with very good safety profiles in young children when antihistamines are truly indicated 1

Clinical Decision Algorithm

For children under 5 years with respiratory symptoms:

1. Determine if symptoms are viral vs. asthma-related 5

   • Most young children with wheeze have viral infections that resolve by age 6
   • Consider asthma predictive index for those with frequent wheezing

2. If viral upper respiratory infection:

   • Avoid all OTC cough/cold medications including antihistamine-decongestant combinations
   • Supportive care only

3. If true asthma requiring treatment:

   • Use inhaled corticosteroids (budesonide nebulizer for ages 1-8 years) as first-line 5
   • Avoid short-acting beta-agonists as monotherapy for chronic control
   • Reassess in 4-6 weeks; if no clear benefit, stop and reconsider diagnosis 5

The combination you've asked about has no role in children under 5 years due to mortality risk, lack of efficacy, and availability of safer, evidence-based alternatives.